Overview

NeuroXess is a Shanghai implantable BCI company. In late 2025 it reported China’s first human implantation of a fully implanted BCI with an integrated battery, performed by a Huashan Hospital team, and said it had completed 54 human BCI implantations since its founding in 2021. The company is now building a dedicated BCI production facility, signalling a shift from lab-bench prototyping to scale manufacturing. Its fully implanted, fully wireless Triple-Full system began a 32-participant registration trial led at Huashan Hospital on 7 July 2026 (NCT07720882) and entered the NMPA’s innovative device review the same month.

Technology

NeuroXess develops polyimide mesh electrodes, a non-penetrating design that conforms to the brain’s surface without piercing cortical tissue. The implant is fully integrated with an internal battery, eliminating external power requirements. Huashan Hospital reported that the first recipient of the battery-powered system reached a decoding rate of 5.2 bits per second in standard tests after training.

Manufacturing

NeuroXess maintains its corporate and research headquarters in Shanghai, but the 14,300-square-metre production facility broke ground in January 2026 in Nanchang’s Ganjiang New Area, Jiangxi province. The “super factory” is designed to deliver tens of thousands of implantable units and surgical robots, and represents a significant step toward mass manufacturing of implantable neural interfaces in China. The Shanghai-HQ / Jiangxi-manufacturing split mirrors a common Chinese deeptech footprint where R&D anchors in a tier-1 city while volume production scales in a province with lower land and labour costs.

Competitive Position

NeuroXess is positioned as a direct global competitor to Neuralink and other Western BCI companies, leveraging government support, lower development costs, and a rapidly maturing regulatory environment to accelerate commercial timelines. Co-founder Phoenix Peng departed in 2025 to launch Gestala, an ultrasound-focused BCI startup.